Background: Juvenile myelomonocytic leukaemia (JMML) and chronic myelomonocytic leukaemia (CMML) are myelodysplastic myeloproliferative (MDS/MPN) neoplasms with unfavourable prognosis and without effective chemotherapy treatment. Trabectedin is a DNA minor groove binder acting as a modulator of transcription and interfering with DNA repair mechanisms; it causes selective depletion of cells of the myelomonocytic lineage. We hypothesised that trabectedin might have an antitumour effect on MDS/MPN. Methods: Malignant CD14+ monocytes and CD34+ haematopoietic progenitor cells were isolated from peripheral blood/bone marrow mononuclear cells. The inhibition of CFU-GM colonies and the apoptotic effect on CD14+ and CD34+ induced by trabectedin were evaluated. Trabectedin's effects were also investigated in vitro on THP-1, and in vitro and in vivo on MV-4-11 cell lines. Results: On CMML/JMML cells, obtained from 20 patients with CMML and 13 patients with JMML, trabectedin - at concentration pharmacologically reasonable, 1-5 nM - strongly induced apoptosis and inhibition of growth of haematopoietic progenitors (CFU-GM). In these leukaemic cells, trabectedin downregulated the expression of genes belonging to the Rho GTPases pathway (RAS superfamily) having a critical role in cell growth and cytoskeletal dynamics. Its selective activity on myelomonocytic malignant cells was confirmed also on in vitro THP-1 cell line and on in vitro and in vivo MV-4-11 cell line models. Conclusions: Trabectedin could be good candidate for clinical studies in JMML/CMML patients.
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms / M. Romano, M.G. Della Porta, A. Gallì, N. Panini, S.A. Licandro, E. Bello, I. Craparotta, V. Rosti, E. Bonetti, R. Tancredi, M. Rossi, L. Mannarino, S. Marchini, L. Porcu, C.M. Galmarini, A. Zambelli, M. Zecca, F. Locatelli, M. Cazzola, A. Biondi, A. Rambaldi, P. Allavena, E. Erba, M. D'Incalci. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 116:3(2017), pp. 335-343.
|Titolo:||Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms|
|Parole Chiave:||apoptosis; CMML; cytotoxicity; gene expression; JMML; Rho GTPases; trabectedin; Oncology; Cancer Research|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||2017|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1038/bjc.2016.424|
|Appare nelle tipologie:||01 - Articolo su periodico|